Biodexa Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1487.9%.

Top 23 shareholders own 57.99% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
28.9%	Brio Capital L.P.	167,681	US$835.1k	194%	24.32%
8.12%	Cavalry Fund I Management, LLC	47,193	US$235.0k	1.1%	69.39%
7.24%	Ionic Ventures, LLC	42,080	US$209.6k	141%	no data
2.48%	GS Capital Partners LLC	14,385	US$71.6k	0%	no data
2.44%	Bukwang Pharmaceutical Co., Ltd.	14,177	US$70.6k	0%	no data
2.44%	Melior Pharmaceuticals, Inc	14,177	US$70.6k	0%	no data
1.76%	UBS Asset Management AG	10,217	US$50.9k	2,460%	no data
1.53%	Bigger Capital, LLC	8,911	US$44.4k	0%	0.28%
1.47%	District 2 Capital LP	8,523	US$42.4k	0%	0.55%
0.95%	Mercer Street Capital Partners, LLC	5,542	US$27.6k	13.5%	23.74%
0.22%	Two Sigma Securities, LLC, Asset Management Arm	1,303	US$6.5k	58.5%	no data
0.17%	Armistice Capital LLC	998	US$5.0k	0%	no data
0.098%	Morgan Stanley, Investment Banking and Brokerage Investments	572	US$2.8k	57,100%	no data
0.083%	Haitong International Asset Management (HK) Ltd.	482	US$2.4k	0%	no data
0.045%	Shamir Capital	262	US$1.3k	0%	0.07%
0.041%	Rhumbline Advisers Ltd Partnership	241	US$1.2k	123%	no data
0.0069%	Contravisory Investment Management, Inc.	40	US$199.3	0%	no data
0.0029%	Walleye Capital LLC	17	US$84.8	0%	no data
0.0019%	GAMMA Investing LLC	11	US$54.7	-92.9%	no data
0.00017%	Simon Turton	1	US$4.9	0%	no data
0.00017%	Stephen Stamp	1	US$4.9	0%	no data
0.00017%	Sijmen de Vries	1	US$4.9	0%	no data
0.00017%	Hantz Financial Services, Inc., Asset Management Arm	1	US$4.9	0%	no data